DK1407006T3 - Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler - Google Patents

Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler

Info

Publication number
DK1407006T3
DK1407006T3 DK02787945T DK02787945T DK1407006T3 DK 1407006 T3 DK1407006 T3 DK 1407006T3 DK 02787945 T DK02787945 T DK 02787945T DK 02787945 T DK02787945 T DK 02787945T DK 1407006 T3 DK1407006 T3 DK 1407006T3
Authority
DK
Denmark
Prior art keywords
infected cells
recovery
virus
purification
pox virus
Prior art date
Application number
DK02787945T
Other languages
Danish (da)
English (en)
Inventor
Karl Heller
Jutta Kramer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1407006T3 publication Critical patent/DK1407006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK02787945T 2001-12-20 2002-12-13 Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler DK1407006T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101928 2001-12-20

Publications (1)

Publication Number Publication Date
DK1407006T3 true DK1407006T3 (da) 2005-12-12

Family

ID=8160920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787945T DK1407006T3 (da) 2001-12-20 2002-12-13 Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler

Country Status (22)

Country Link
US (1) US7056723B2 (pl)
EP (1) EP1407006B9 (pl)
JP (2) JP5322252B2 (pl)
KR (1) KR100947976B1 (pl)
CN (1) CN1289663C (pl)
AT (1) ATE302268T1 (pl)
AU (1) AU2002352247B2 (pl)
BR (1) BRPI0215003B1 (pl)
CA (1) CA2467099C (pl)
DE (1) DE60205631T2 (pl)
DK (1) DK1407006T3 (pl)
EA (1) EA006485B1 (pl)
ES (1) ES2247404T3 (pl)
HU (1) HU227507B1 (pl)
IL (2) IL161526A0 (pl)
MX (1) MXPA04006001A (pl)
NO (1) NO335975B1 (pl)
NZ (1) NZ533586A (pl)
PL (1) PL205929B1 (pl)
SI (1) SI1407006T1 (pl)
UA (1) UA77735C2 (pl)
WO (1) WO2003054175A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
PL212047B1 (pl) * 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
WO2006052826A2 (en) * 2004-11-05 2006-05-18 The Government Of The United States Of America As Represented By The Secretary Methods for preparing cells and viruses
US7625570B1 (en) * 2005-03-10 2009-12-01 The Regents Of The University Of California Methods for purifying adeno-associated virus
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
JP2010526546A (ja) * 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
RU2011148791A (ru) * 2009-05-12 2013-06-20 Трансген Са Иммортализованные линии клеток птиц и их применение
FR2953686B1 (fr) * 2009-12-14 2012-11-02 Agronomique Inst Nat Rech Procede pour reduire la teneur bacterienne d'un milieu alimentaire et/ou biologique d'interet, contenant des gouttelettes lipidiques
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
CN102353792A (zh) * 2011-07-07 2012-02-15 贵州大学 一种基于gpv p32蛋白的间接elisa试剂盒及制备方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
JP2025525380A (ja) 2022-06-29 2025-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換え改変ｓａＲＮＡ（ＶＲＰ）及びワクシニアウイルスアンカラ（ＭＶＡ）プライム－ブーストレジメン
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
CN115197966A (zh) * 2022-08-15 2022-10-18 深圳源兴基因技术有限公司 一种利用生物反应器大规模生产重组痘苗病毒载体的方法
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877898A (en) 1956-12-06 1961-09-20 Apv Co Ltd A new or improved method of liberating enzymes
JPS5328989B2 (pl) 1974-05-27 1978-08-17
CH621573A5 (en) 1976-08-05 1981-02-13 Vnii Biosinteza Belkovykh Vesc Process for the continuous disintegration of microorganism cells and system for carrying out this process
JPS54154594A (en) 1978-05-25 1979-12-05 Sumitomo Chem Co Ltd Extraction of glucose isomerase
WO1991001367A1 (en) 1989-07-20 1991-02-07 Bioeng, Inc. Supercritical fluid disruption of and extraction from microbial cells
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
TW426733B (en) 1995-10-06 2001-03-21 Merck & Co Inc Method of disrupting cultured cells using an impinging jet device
AU4556597A (en) 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US5721120A (en) 1996-10-02 1998-02-24 Merck & Co., Inc. Method of disrupting cultured cells using an impinging jet device
NZ299720A (en) * 1996-11-08 1999-07-29 Howick Engineering Ltd Epicyclic input/output annuli of same pcd, with planetary input/output gear sets, and with only one set having aligned teeth
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US6000551A (en) 1996-12-20 1999-12-14 Eastman Chemical Company Method for rupturing microalgae cells
FR2787465A1 (fr) * 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
EP1155120B1 (fr) * 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
DE19918619A1 (de) 1999-04-23 2000-10-26 Rhein Biotech Proz & Prod Gmbh Verfahren zum Gewinnen von rekombinantem HBsAg
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen

Also Published As

Publication number Publication date
ATE302268T1 (de) 2005-09-15
EA200400833A1 (ru) 2004-12-30
JP2010046093A (ja) 2010-03-04
AU2002352247B2 (en) 2008-08-07
AU2002352247A1 (en) 2003-07-09
DE60205631T2 (de) 2006-06-08
EP1407006B1 (en) 2005-08-17
IL161526A (en) 2009-11-18
HUP0402337A3 (en) 2010-01-28
HU227507B1 (hu) 2011-07-28
BRPI0215003B1 (pt) 2017-03-14
CN1606616A (zh) 2005-04-13
EP1407006B9 (en) 2006-10-18
HK1071765A1 (en) 2005-07-29
DE60205631D1 (de) 2005-09-22
PL369498A1 (pl) 2005-04-18
CN1289663C (zh) 2006-12-13
CA2467099A1 (en) 2003-07-03
EA006485B1 (ru) 2005-12-29
KR100947976B1 (ko) 2010-03-15
NO335975B1 (no) 2015-04-07
ES2247404T3 (es) 2006-03-01
CA2467099C (en) 2013-01-29
UA77735C2 (en) 2007-01-15
US7056723B2 (en) 2006-06-06
KR20040070263A (ko) 2004-08-06
IL161526A0 (en) 2004-09-27
JP2005512565A (ja) 2005-05-12
HUP0402337A2 (hu) 2005-01-28
WO2003054175A1 (en) 2003-07-03
JP5322252B2 (ja) 2013-10-23
SI1407006T1 (sl) 2006-04-30
NZ533586A (en) 2005-02-25
US20040265986A1 (en) 2004-12-30
MXPA04006001A (es) 2005-08-19
BR0215003A (pt) 2004-11-09
NO20043181L (no) 2004-07-19
PL205929B1 (pl) 2010-06-30
EP1407006A1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
DK1407006T3 (da) Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler
NZ600629A (en) Vaccinia virus mutants containing the major genomic deletions of mva
WO2004029781A3 (en) System for analyzing a capital structure
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
DK1514194T3 (da) Autentificering og beskyttelse til ip-applikationsprotokoller baseret på 3gpp-procedurer
DK1100751T3 (da) Fremstilling af anioniske, sammensatte nanomaterialer og deres anvendelse som hjælpestoffer til tilbageholdelse og afvanding ved fremstilling af papir
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
ATE397936T1 (de) Therapeutische verfahren unter verwendung von pflanzlichen zusammensetzungen
DK1780269T3 (da) Virusrensningsmetoder
DK1508047T3 (da) Fremgangsmåde til identifikation af immunoreaktive peptider
NO20025151L (no) Nye forbindelser
PL373992A1 (pl) Sposób hodowli komórek podstawowych i amplifikacji wirusów w warunkach braku surowicy
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
DE60220341D1 (de) Bündelfehlermuster- Erzeugungsverfahren, sowie Bündel und Byte- Fehlererkennung und Korrektur
WO2003016566A3 (en) Improvements relating to capillary gel array analysis
DE602004009743D1 (de) Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
ATE313641T1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
WO2004044182A3 (en) Highly permissive cell lines for hepatitis c virus replication
NO20061326L (no) Anvendelse av ekstrakter fra knottre
ATE491952T1 (de) Screening auf inhibitoren des eindringens von hepatitis-c-virus
DE60132588D1 (de) Modifizierte sulfonamidpolymere
DK1129344T3 (da) Fremgangsmåder og formuleringer til separation af biologiske makromolekyler
WO2003046137A3 (en) Hiv envelope v3-ccr5 binding site immunogen
NO980906L (no) Nye, antikonvulsivt virkende 1-ar(alk)yl-imidazolin-2-oner, som i 4-stilling inneholder en disubstituert aminrest og en fremgangsmåte for deres fremstilling